Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

Benefit Observed at 12 months Postoperatively Following Single Administration

SAN DIEGO, CA, USA I July 09, 2018 I Cytori Therapeutics, Inc. (Nasdaq:CYTX) announced publication in the peer-reviewed journal, Urology, of “A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-label Phase I Clinical Trial”.

The trial of Adipose-Derived Regenerative Cells (ADRCs) or Cytori Cell Therapy™ in erectile dysfunction (ED) following radical prostatectomy was performed by investigators from the Danish Centre for Regenerative Medicine and Odense University Hospital, Odense, Denmark.

In the trial, 21 patients with ED after radical prostatectomy (RP), with no signs of recovery following conventional therapy, received a single intra-cavernous injection of autologous ADRCs. Six men were incontinent, and 15 were continent at inclusion. Safety and efficacy (sexual function) were evaluated over 12 months through assessment of adverse events and use of validated questionnaires including the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score (EHS).

The mean age at baseline was 60.2 years (range 46-69). The approach was deemed safe with no serious adverse events reported. At 12 months following treatment with cell therapy, erectile function assessed using the IIEF-5 showed a statistically significant improvement from a median baseline score of six to a median of eight; p=0.004. Subset analysis of the 15 patients with urinary continence at baseline, showed substantially greater improvement from a median baseline score of six to 13; p=0.012.

At 12 months after surgery, median EHS was unchanged in the combined group of 21 patients. However, patients in the continent subset exhibited statistically significant improvement in EHS from a baseline median score of one to a median of two at 12 months; p=0.03. Further, 53.3% or eight out of 15 continent patients reported recovered function sufficient for completion of intercourse. 

ED and urinary incontinence are serious issues for many men following RP. Cytori Cell Therapy™ is being used to address both of these medical problems. Thus, in addition to the work published in this report, the company has fully enrolled the Autologus Aipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence (ADRESU) trial of Cytori Cell Therapy™ in men with stress urinary incontinence following RP. The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) one year following treatment.  Data from ADRESU are anticipated in the first half of 2019.

ADRESU is an investigator-initiated, multicenter, 45 patient, open-label, single arm clinical trial of Cytori’s ECCI-50 cellular therapeutic, comprised of Celution®-prepared autologous ADRCs and Adipose Cells. The ADRESU trial was based on a promising pilot trial with short-term data of eleven patients published in the International Journal of Urology in 2014 and long-term data of 14 patients presented at the International Continence Society in 2017, which “demonstrated that transurethral injection of autologous ADRCs can be a safe and effective treatment modality for postprostatectomy incontinence”.  Details of the ADRESU protocol and trial can be found on BMC Urology, clinicaltrials.gov and the University Hospital Medical Information Network website.

About Cytori
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com.

SOURCE: Cytori

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top